The FDA (Food & Drug Administration) approved use of Abilify for maintenance of bipolar disorder in 2005. But a recent article published in the open access journal PLoS Medicine (Tsai, et al) looks critically at the science behind the decision to approve Abilify. The results were one blind, randomized trial sponsored by the pharmaceutical company that makes Abilify, Bristol Meyers Squibb. Article exposes flaws in trial to show we currently do not have enough evidence to know whether or not Abilify is effective in the maintenance of bipolar disorder. Article also features step-by-step advice for people currently taking Abilify.